🇺🇸 FDA
Patent

US 10479783

Compositions and methods for inhibition of the JAK pathway

granted A61PA61P27/00A61P27/02

Quick answer

US patent 10479783 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61P, A61P27/00, A61P27/02, A61P27/04, A61P27/06